ARCHIVES

SWOG Opens Phase II Trial Of CuraGen’s HDAC Inhibitor For B-Cell Lymphoma

This article is from The Cancer Letter archive.

Vol. 29 No. 9 | September 29, 2006

Download PDF Visit The Full Archive

Related Articles

Some NCI Responses To CCOP Letters Of Intent Missing; NCAB Debates Pediatric Issues

October 8, 1982

Drug Development Gets Extra $500,000

November 18, 1977

ODAC Reviews Post-Marketing Studies for Eight Indications

February 21, 2003

DCCP Board Approves Concept Of NMR Interintuitional Clinical Research

January 27, 1984

Survey Finds Misconceptions About Cancer Worldwide

August 29, 2008

In Brief: Bishop Named Interim Chairman of NCAB; AACI Elects Wicha president, Herberman VP

December 12, 1997